High baseline sBCMA predicts the clinical outcome of anti-BCMA TCE therapy in the MajesTEC-1 study cohort. (A) Box plot representing the median sBCMA levels (ng/mL), (B) mBCMA levels (in MESF), and (C) sBCMA:mBCMA in responding vs nonresponding patients. (D) Dot plot representing the ratio between mBCMA and sBCMA and the bone marrow plasma cell percentage (%BMPC). (E) PFS of patients treated with teclistamab at recommended phase 2 (RP2D) based on sBCMA cutoff of 400 ng/mL. (F) PFS of patients treated with teclistamab RP2D based on the sBCMA median cutoff. MESF, molecules of equivalent soluble fluorochrome.